Ramaswamy's Roivant Inks $650M R&D Deal With This Tiny Diabetes Biotech Post author:Sam Post published:February 11, 2018 Post category:BioPharma With the deal in hand, Roivant has stepped into the world of metabolic diseases. Source: BioSpace You Might Also Like GlaxoSmithKline Ditches Ionis Pharma's Inotersen and IONIS-FB-LRx August 10, 2017 OvaScience To Host Fourth Quarter And Fiscal Year 2016 Financial Results Conference Call February 23, 2017 Athenex Moves Forward With $205M New York Plant January 11, 2018
OvaScience To Host Fourth Quarter And Fiscal Year 2016 Financial Results Conference Call February 23, 2017
